Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Workhorse Q4 and Full Year 2025 Earnings Call - Merger with Motiv sets path to profitability with 2,500-unit breakeven and $20M synergies
Workhorse closed its merger with Motiv in December 2025 and used the combination to reset strategy, manufacturing, and cost structure. Management says the merged company already has scale in the field...
- Merger closed December 15, 2025, with Motiv accounted for on a reverse merger basis; Q4 and FY results reflect Motiv standalone through Dec 15 and combined thereafter.
- Management frames the merger as transformational, combining product portfolios across Class 4, 5, and 6 and more than $860 million of prior invested capital.
- Installed base and validation: more than 1,100 vehicles operating with over 20 million cumulative miles, serving 10 of North America’s largest medium-duty fleets, with documented repeat purchase behavior.
- +11 more takeaways
Banzai Q4 2025 Earnings Call - Acquisition-Fueled Revenue Surge, ConnectAndSell to More Than Double Run Rate
Banzai closed 2025 with a sprint. Revenue jumped 169% for the year to $12.2 million, Q4 revenue rose 116% to $2.8 million, and gross margin expanded to roughly 82% as video and AI assets like Vidello ...
- Revenue grew 116% year-over-year in Q4 2025 to $2.8 million, and full year 2025 revenue rose 169% to $12.2 million, driven largely by acquisitions Vidello and OpenReel.
- Gross profit expanded 221% year-over-year to $10.0 million for 2025, lifting gross margin to approximately 82% from 68.6% in 2024.
- Operating expenses rose sharply to $28.4 million in 2025, primarily due to the addition of acquired businesses, contributing to a full year net loss of $22.5 million (improved from $31.5 million).
- +12 more takeaways
Barfresh Food Group Q4 2025 Earnings Call - Arps Dairy Buy Gives Control of Manufacturing, Promises Path to $200M Revenue Capacity
Barfresh closed 2025 with record revenue but squeezed margins, after a year defined by a strategic acquisition and a financing deal that retools the company's operating model. The October acquisition ...
- Record revenue for 2025: $14.2 million, up 33% year over year; Q4 2025 revenue was $5.4 million, a 94% y/y increase.
- Acquisition of Arps Dairy (Oct 2025) added a 15,000 sq ft processing plant and a 44,000 sq ft manufacturing facility in Defiance, Ohio, shifting production in-house.
- Post-acquisition production mix now roughly 90% in-house, reducing dependence on third-party co-manufacturers that previously constrained growth.
- +12 more takeaways
Edible Garden AG Q4 2025 Earnings Call - RTD push aims to pivot company to higher-margin CPG
Edible Garden spent 2025 reshaping itself from a controlled-environment produce supplier into a broader CPG player, leaning hard into ready-to-drink protein and nutraceuticals. Management reported dis...
- Distribution and retail wins: management expanded national distribution to nearly 6,000 store locations, adding more than 700 incremental retail placements in Q4, including Kroger, Weis Markets, Safeway, The Fresh Market, Busch’s, Wakefern and others.
- Q4 revenue and YoY: revenue for the three months ended December 31, 2025 was approximately $4.1 million, up from $3.9 million in Q4 2024.
- Q4 cost and gross results: cost of goods sold in Q4 was about $5.3 million versus $3.8 million a year earlier, producing a Q4 gross loss of approximately $1.2 million, compared with flat gross profit in Q4 2024.
- +12 more takeaways
Rekor Systems, Inc. FY2025 Earnings Call - Margin Inflection as Company Repositions Toward Recurring Software and Onshored Engineering
Rekor says FY2025 was a turning point, delivering modest top-line growth while cutting costs and shifting the business mix toward higher-margin software and data subscriptions. Revenue rose to $48.5 m...
- Revenue for the year ended December 31, 2025 was $48.5 million, up 5% from $46.0 million in 2024.
- Recurring revenue was $23.9 million in 2025, up 6% year-over-year, roughly a 50/50 split between recurring and equipment revenue.
- Remaining performance obligations rose to $25.9 million as of December 31, 2025, an increase of nearly 80% from a year earlier, cited as pipeline momentum into 2026.
- +13 more takeaways
Co-Diagnostics Inc. Q4 2025 Earnings Call - India TB commercialization becomes the focus as losses mount
Co-Diagnostics used the call to signal a clear pivot: India and TB diagnostics are now the most immediate commercial levers. Management highlighted CoSara’s manufacturing license, 15 locally cleared t...
- Nasdaq relisting completed, management emphasizing forward execution after the temporary listing disruption.
- Company organized growth around four pillars: clinical regulatory progress, CoSara/India strategy and alternatives, CoMira expansion in Saudi and MENA, and AI-driven platform capabilities.
- CoSara joint venture in India received CDSCO license to manufacture the PCR Pro instrument, and CoSara now services hundreds of labs with 15 PCR tests cleared locally.
- +12 more takeaways
Newton Golf Company FY2025 Earnings Call - Record Revenue Growth, But Cash Runway Tight
Newton Golf posted a startling top-line sprint in FY2025, with revenue up 136% to $8.1 million driven by a 157% surge in direct-to-consumer sales and broad adoption of its Newton Motion shaft platform...
- Revenue jumped 136% year over year to $8.1 million in FY2025, a new company record.
- Direct-to-consumer sales drove most of the gain, rising 157% to $7.4 million.
- Newton Motion shaft platform showed strong traction, with Fast Motion launched in 2025 becoming the company’s best-selling product.
- +13 more takeaways
Knightscope Q4 2025 Earnings Call - Event Risk acquisition recasts Knightscope as a managed-service play to scale into a $230B TAM
Knightscope closed 2025 with modest revenue growth, widening losses, and a cash cushion reset by financings, while announcing a strategic pivot. The company bought Event Risk to combine human guarding...
- Strategic pivot: Knightscope acquired Event Risk and intends to sell an integrated managed service combining human guards, robotics, and software, reframing the company as an Autonomous Security Force and a managed service provider.
- TAM remains $230 billion as presented on knightscope.com/america, management says the acquisition accelerates ability to penetrate that market rather than changing the TAM itself.
- Q4 2025 revenue declined ~9.8% year-over-year, driven largely by supply-chain constraints that delayed ECD product deliveries; services revenue was largely unchanged in the quarter.
- +12 more takeaways
American Shared Hospital Services Q4 2025 Earnings Call - Shift to Direct Patient Care Now Majority, But Cash and Covenant Pressure Mounts
Management says 2025 was a year of structural change, with a deliberate pivot from equipment leasing into direct patient care. The shift is real and measurable: direct patient care now generates the m...
- Company completed a strategic shift in 2025 toward a direct patient care model, which now represents the majority of total revenue.
- Total revenue for full-year 2025 was $28.1 million, roughly flat versus $28.3 million in 2024.
- Direct patient care services revenue grew 23.7% to $15.5 million in 2025, while leasing revenue declined to $12.6 million.
- +14 more takeaways
Imunon Q4 2025 Earnings Call - IMNN-001 shows unprecedented phase II OS benefit, OVATION 3 enrolling ahead of plan
Imunon opened the year riding a breakthrough phase II readout for IMNN-001, reporting a final overall survival improvement of 14.7 months in OVATION 2 and an even larger effect in the subgroup receivi...
- Final OVATION 2 phase II overall survival benefit increased to 14.7 months in the company’s final review of the trial.
- Patients who received PARP inhibitor maintenance in OVATION 2 showed a median overall survival improvement of more than two years versus control.
- OVATION 3 is a one-to-one randomized pivotal phase III that mirrors the phase II backbone, testing IMNN-001 plus standard neoadjuvant and adjuvant chemotherapy including interval debulking surgery vs standard of care alone.
- +12 more takeaways